Seeking Alpha

Novartis (NVS) plans to file for Japanese and EU approval of QVA149 - a therapy that combines...

Novartis (NVS) plans to file for Japanese and EU approval of QVA149 - a therapy that combines two of the company's other drugs and is used to treat smoker's cough - later this year after it met expectations in final trials. Yesterday, the FDA authorized a new dosage of Novartis' cancer drug Afinitor so it can be used to treat children with a rare brain tumor. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|